跳至主要内容
临床试验/IRCT20130812014333N147
IRCT20130812014333N147招募中3 期

Comparative assessment of the efficacy and safety of addon treatment with Sofosbuvir-Daclatasvir”, Lithium”,and Trifluoprazine” to standard of care in three groups of patients with COVID-19

Kermanshah University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age over 18 years
  • Absolute lymphocyte count <1100 / ML or SaO2 <93

排除标准

  • Pregnancy or breast-feeding
  • The physician's decision that the trial is not in the patient's interest
  • Any circumstances that do not allow the treatment protocol to be followed easily
  • A history of known allergies to Sofosbuvir-Velp, Trifluoprazine, Lithium and Trihexyphenidyl
  • Drugs that their concomitant use with standard treatment or Sofosbuvir-Velpatasvir, Trifluoprazine, Lithium, and Trihexyphenidyl are contraindicated and can not be discontinued.

研究者

相似试验

Comparative assessment of the efficacy and safety of... | 临床试验